Methods
We compared different PK exposures using Monte Carlo simulations based
on a previously published population pharmacokinetic model in patients
with rheumatoid arthritis, externally validated using both independent
data in lupus erythematous patients and recent data in French COVID-19
patients. Clinical efficacy and safety information from COVID-19
patients treated with HCQ were used to contextualize and assess the
actual clinical value of the model predictions.